Truncated and full-length thioredoxin-1 have opposing activating and inhibitory properties for human complement with relevance to endothelial surfaces

Journal of Immunology

Volumn 188, Issue 8, 2012, Pages 4103-4112

  King, Ben C ^a   Nowakowska, Justyna ^a   Karsten, Christian M ^b   Köhl, Jörg ^b,c   Renström, Erik ^d   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF CINCINNATI   (United States)

^d LUND UNIVERSITY DIABETES CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYSTEINE; GLYCINE; PROLINE; THIOREDOXIN; THIOREDOXIN 1; THIOREDOXIN 80; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG BINDING SITE; ENDOTHELIUM CELL; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C4B-BINDING PROTEIN; COMPLEMENT C5A; COMPLEMENT FACTOR H; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PERITONITIS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; THIOREDOXINS;

EID: 84860320635     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101295     Document Type: Article

References (54)

1. Jones, D. P. 2008. Radical-free biology of oxidative stress. Am. J. Physiol. Cell Physiol. 295: C849-C868.
2. Rubartelli, A., A. Bajetto, G. Allavena, E. Wollman, and R. Sitia. 1992. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J. Biol. Chem. 267: 24161-24164.
3. Hofer, S., C. Rosenhagen, H. Nakamura, J. Yodoi, C. Bopp, J. B. Zimmermann, M. Goebel, P. Schemmer, K. Hoffmann, K. Schulze-Osthoff, et al. 2009. Thioredoxin in human and experimental sepsis. Crit. Care Med. 37: 2155-2159.
4. Pekkari, K., R. Gurunath, E. S. Arner, and A. Holmgren. 2000. Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J. Biol. Chem. 275: 37474-37480. (Pubitemid 32004854)
5. Pekkari, K., J. Avila-Cariño, A. Bengtsson, R. Gurunath, A. Scheynius, and A. Holmgren. 2001. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. Blood 97: 3184-3190.
6. Nakamura, H., L. A. Herzenberg, J. Bai, S. Araya, N. Kondo, Y. Nishinaka, L. A. Herzenberg, and J. Yodoi. 2001. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc. Natl. Acad. Sci. USA 98: 15143-15148. (Pubitemid 34013983)
7. Zhang, J., F. Chen, T. Nakamura, T. Fujinaga, A. Aoyama, H. Hamakawa, H. Sakai, Y. Hoshino, J. Yodoi, H. Wada, et al. 2009. Protective effect of thioredoxin perfusion but not inhalation in warm ischemic-reperfused rat lungs. Redox Rep. 14: 75-81.
8. Shibuki, H., N. Katai, S. Kuroiwa, T. Kurokawa, J. Yodoi, and N. Yoshimura. 1998. Protective effect of adult T-cell leukemia-derived factor on retinal ischemia-reperfusion injury in the rat. Invest. Ophthalmol. Vis. Sci. 39: 1470-1477. (Pubitemid 28307373)
9. Fukuse, T., T. Hirata, H. Yokomise, S. Hasegawa, K. Inui, A. Mitsui, T. Hirakawa, S. Hitomi, J. Yodoi, and H. Wada. 1995. Attenuation of ischaemia reperfusion injury by human thioredoxin. Thorax 50: 387-391.
10. Tao, L., E. Gao, N. S. Bryan, Y. Qu, H. R. Liu, A. Hu, T. A. Christopher, B. L. Lopez, J. Yodoi, W. J. Koch, et al. 2004. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. [corrected] Proc. Natl. Acad. Sci. USA 101: 11471-11476. (Pubitemid 39038371)
11. Arumugam, T. V., I. A. Shiels, T. M. Woodruff, D. N. Granger, and S. M. Taylor. 2004. The role of the complement system in ischemia-reperfusion injury. Shock 21: 401-409.
12. Czermak, B. J., V. Sarma, C. L. Pierson, R. L. Warner, M. Huber-Lang, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward. 1999. Protective effects of C5a blockade in sepsis. Nat. Med. 5: 788-792. (Pubitemid 29318613)
13. Inomata, Y., H. Tanihara, M. Tanito, H. Okuyama, Y. Hoshino, T. Kinumi, T. Kawaji, N. Kondo, J. Yodoi, and H. Nakamura. 2008. Suppression of choroidal neovascularization by thioredoxin-1 via interaction with complement factor H. Invest. Ophthalmol. Vis. Sci. 49: 5118-5125.
14. Haines, J. L., M. A. Hauser, S. Schmidt, W. K. Scott, L. M. Olson, P. Gallins, K. L. Spencer, S. Y. Kwan, M. Noureddine, J. R. Gilbert, et al. 2005. Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421. (Pubitemid 40530081)
15. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
16. Köhl, J. 2006. The role of complement in danger sensing and transmission. Immunol. Res. 34: 157-176. (Pubitemid 43997968)
17. Ricklin, D., and J. D. Lambris. 2007. Complement-targeted therapeutics. Nat. Biotechnol. 25: 1265-1275. (Pubitemid 350089828)
18. Bora, P. S., J. H. Sohn, J. M. Cruz, P. Jha, H. Nishihori, Y. Wang, S. Kaliappan, H. J. Kaplan, and N. S. Bora. 2005. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J. Immunol. 174: 491-497. (Pubitemid 40007439)
19. Amara, U., M. A. Flierl, D. Rittirsch, A. Klos, H. Chen, B. Acker, U. B. Brückner, B. Nilsson, F. Gebhard, J. D. Lambris, and M. Huber-Lang. 2010. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185: 5628-5636.
20. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegård, J. Köhl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877. (Pubitemid 34925168)
21. Munthe-Fog, L., T. Hummelshøj, B. E. Hansen, C. Koch, H. O. Madsen, K. Skjødt, and P. Garred. 2007. The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand. J. Immunol. 65: 383-392. (Pubitemid 46481107)
22. Munthe-Fog, L., T. Hummelshøj, Y. J. Ma, B. E. Hansen, C. Koch, H. O. Madsen, K. Skjødt, and P. Garred. 2008. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol. Immunol. 45: 2660-2666.
23. 2 fragments of immunoglobulin G. Clin. Chem. 29: 1982-1984. (Pubitemid 13023996)
24. Holmgren, A. 1979. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J. Biol. Chem. 254: 9627-9632. (Pubitemid 10248727)
25. Otto, M., H. Hawlisch, P. N. Monk, M. Müller, A. Klos, C. L. Karp, and J. Köhl. 2004. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J. Biol. Chem. 279: 142-151. (Pubitemid 38044809)
26. Heller, T., M. Hennecke, U. Baumann, J. E. Gessner, A. M. zu Vilsendorf, M. Baensch, F. Boulay, A. Kola, A. Klos, W. Bautsch, and J. Köhl. 1999. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J. Immunol. 163: 985-994. (Pubitemid 29328111)
27. Hara, T., N. Kondo, H. Nakamura, H. Okuyama, A. Mitsui, Y. Hoshino, and J. Yodoi. 2007. Cell-surface thioredoxin-1: possible involvement in thiol-mediated leukocyte-endothelial cell interaction through lipid rafts. Antioxid. Redox Signal. 9: 1427-1437. (Pubitemid 47255023)
28. Skalska, J., P. S. Brookes, S. M. Nadtochiy, S. P. Hilchey, C. T. Jordan, M. L. Guzman, S. B. Maggirwar, M. M. Briehl, and S. H. Bernstein. 2009. Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. PLoS One 4: e8115.
29. Turano, C., S. Coppari, F. Altieri, and A. Ferraro. 2002. Proteins of the PDI family: unpredicted non-ER locations and functions. J. Cell. Physiol. 193: 154-163.
30. Spitzer, D., L. M. Mitchell, J. P. Atkinson, and D. E. Hourcade. 2007. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 179: 2600-2608.
31. Pekkari, K., J. Avila-Cariño, R. Gurunath, A. Bengtsson, A. Scheynius, and A. Holmgren. 2003. Truncated thioredoxin (Trx80) exerts unique mitogenic cytokine effects via a mechanism independent of thiol oxido-reductase activity. FEBS Lett. 539: 143-148. (Pubitemid 36351303)
32. Cortes-Bratti, X., E. Bassères, F. Herrera-Rodriguez, S. Botero-Kleiven, G. Coppotelli, J. B. Andersen, M. G. Masucci, A. Holmgren, E. Chaves-Olarte, T. Frisan, and J. Avila-Cariño. 2011. Thioredoxin 80-activated-monocytes (TAMs) inhibit the replication of intracellular pathogens. PLoS One 6: e16960.
33. Fosbrink, M., F. Niculescu, V. Rus, M. L. Shin, and H. Rus. 2006. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J. Biol. Chem. 281: 19009-19018. (Pubitemid 44035404)
34. Fischetti, F., and F. Tedesco. 2006. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity 39: 417-428. (Pubitemid 44269620)
35. Skeie, J. M., J. H. Fingert, S. R. Russell, E. M. Stone, and R. F. Mullins. 2010. Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. Invest. Ophthalmol. Vis. Sci. 51: 5336-5342.
36. Kilgore, K. S., J. P. Shen, B. F. Miller, P. A. Ward, and J. S. Warren. 1995. Enhancement by the complement membrane attack complex of tumor necrosis factor-α-induced endothelial cell expression of E-selectin and ICAM-1. J. Immunol. 155: 1434-1441.
37. Schroeder, B. O., Z. Wu, S. Nuding, S. Groscurth, M. Marcinowski, J. Beisner, J. Buchner, M. Schaller, E. F. Stange, and J. Wehkamp. 2011. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature 469: 419-423.
38. Zoppi, M., M. Weiss, U. E. Nydegger, T. Hess, and P. J. Späth. 1990. Recurrent meningitis in a patient with congenital deficiency of the C9 component of complement: first case of C9 deficiency in Europe. Arch. Intern. Med. 150: 2395-2399. (Pubitemid 20365252)
39. Nakamura, T., Y. Hoshino, A. Yamada, A. Teratani, S. Furukawa, H. Okuyama, S. Ueda, H. Wada, J. Yodoi, and H. Nakamura. 2007. Recombinant human thioredoxin-1 becomes oxidized in circulation and suppresses bleomycin-induced neutrophil recruitment in the rat airway. Free Radic. Res. 41: 1089-1098. (Pubitemid 47470846)
40. Huber-Lang, M., V. J. Sarma, K. T. Lu, S. R. McGuire, V. A. Padgaonkar, R. F. Guo, E. M. Younkin, R. G. Kunkel, J. Ding, R. Erickson, et al. 2001. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166: 1193-1199. (Pubitemid 32060279)
41. Nakamura, H., Y. Hoshino, H. Okuyama, Y. Matsuo, and J. Yodoi. 2009. Thioredoxin 1 delivery as new therapeutics. Adv. Drug Deliv. Rev. 61: 303-309.
42. Shashidharamurthy, R., R. A. Hennigar, S. Fuchs, P. Palaniswami, M. Sherman, and P. Selvaraj. 2008. Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcg receptors and can be effectively blocked by decoy Fcγ receptors. Blood 111: 894-904.
43. Heller, T., J. E. Gessner, R. E. Schmidt, A. Klos, W. Bautsch, and J. Köhl. 1999. Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. J. Immunol. 162: 5657-5661. (Pubitemid 29314912)
44. Köhl, J., and J. E. Gessner. 1999. On the role of complement and Fcg-receptors in the Arthus reaction. Mol. Immunol. 36: 893-903. (Pubitemid 30100842)
45. Godau, J., T. Heller, H. Hawlisch, M. Trappe, E. Howells, J. Best, J. Zwirner, J. S. Verbeek, P. M. Hogarth, C. Gerard, et al. 2004. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 173: 3437-3445. (Pubitemid 39142055)
46. Zhang, Y., B. F. Ramos, and B. A. Jakschik. 1991. Augmentation of reverse arthus reaction by mast cells in mice. J. Clin. Invest. 88: 841-846.
47. Höpken, U. E., B. Lu, N. P. Gerard, and C. Gerard. 1997. Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J. Exp. Med. 186: 749-756. (Pubitemid 27381539)
48. Ramos, B. F., Y. Zhang, and B. A. Jakschik. 1994. Neutrophil elicitation in the reverse passive Arthus reaction: complement-dependent and -independent mast cell involvement. J. Immunol. 152: 1380-1384.
49. Sjöberg, A., P. Onnerfjord, M. Mörgelin, D. Heinegård, and A. M. Blom. 2005. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J. Biol. Chem. 280: 32301-32308. (Pubitemid 41361839)
50. Sjöberg, A. P., L. A. Trouw, and A. M. Blom. 2009. Complement activation and inhibition: a delicate balance. Trends Immunol. 30: 83-90.
51. Trouw, L. A., A. A. Bengtsson, K. A. Gelderman, B. Dahlbäck, G. Sturfelt, and A. M. Blom. 2007. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J. Biol. Chem. 282: 28540-28548. (Pubitemid 47606049)
52. Lemarechal, H., P. Anract, J. L. Beaudeux, D. Bonnefont-Rousselot, O. G. Ekindjian, and D. Borderie. 2007. Expression and extracellular release of Trx80, the truncated form of thioredoxin, by TNF-α- and IL-1β-stimulated human synoviocytes from patients with rheumatoid arthritis. Clin. Sci. 113: 149-155. (Pubitemid 47237912)
53. Pekkari, K., and A. Holmgren. 2004. Truncated thioredoxin: physiological functions and mechanism. Antioxid. Redox Signal. 6: 53-61. (Pubitemid 38063975)
54. Newman, G. W., M. K. Balcewicz-Sablinska, J. R. Guarnaccia, H. G. Remold, and D. S. Silberstein. 1994. Opposing regulatory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of human immunodeficiency virus 1. J. Exp. Med. 180: 359-363. (Pubitemid 24181085)